Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Rita A Karachun is Director at Coherus Oncology. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 9, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
As of the latest filing on , Rita A Karachun reported holding 30,000 shares of Coherus Oncology (CHRS), worth about $15K at the last close of $1 (Nov 16, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Coherus Oncology CHRS | 30,000 | 30K direct | $1 | $15K | Jun 5, 2026 |
Is this Rita A Karachun’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Coherus OncologyCHRS
2 disclosures · Jun 2026
Jun 5, 202630Kdisclosed Jun 9
DetailsOfficial recordJun 5, 202660Kdisclosed Jun 9
DetailsOfficial recordOn the latest SEC Form 4, dated Jun 5, 2026, Rita A Karachun reported holding 30,000 shares of Coherus Oncology (CHRS). At the last close of $1 on Nov 16, 2026, that is about $15K. This is the stake disclosed in filings, not a net worth.
Rita A Karachun has no open-market purchase on record since 2017. Sales in 6 of the 10 years since 2017.
In SEC filings since 2017: no open-market purchase is on record; the latest open-market sale is from 2023.
Merck (MRK), from 2017 to 2023: 0 purchases and 6 sales.
Rita A Karachun has no open-market purchase on record since 2017. Sales in 6 of the 10 years since 2017.
Rita A Karachun reported 0 open-market purchases and 6 sales since 2017; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $1.87M1×1 trade |
| 2022 | — | $3.21M1×1 trade |
| 2021 | — | $2.21M1×1 trade |
| 2019 | — | $5.11M1×1 trade |
| 2018 | — | $325K1×1 trade |
| 2017 | — | $191K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Rita A Karachun reported 0 open-market purchases and 6 sales here, 2017 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.